References
- Agresti, A. (2012). Categorical Data Analysis, 3rd ed. New York, NY: Wiley.
- Altman, D. G., Royston, P. (2006). The cost of dichotomising continuous variables. British Medical Journal 332:1080. (doi: 10.1136/bmj.332.7549.1080).
- Bickel, P. J., Klaassen, C. A. J., Ritov, Y., Wellner, J. A. (1993). Efficient and Adaptive Estimation for Semiparametric Models. Baltimore, MD: Johns Hopkins University Press.
- European Medicines Agency. (2005). Guideline on the Choice of the Non-Inferiority Margin. URL http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf.
- Fedorov, V., Mannino, F., Zhang, R. (2009). Consequences of dichotomization. Pharmaceutical Statistics 8:50–61.
- Food and Drug Administration. (2006). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Washington, DC: DHHS.
- International Conference on Harmonisation. (1998). Harmonized Tripartite Guideline Statistical Principles for Clinical Trials: E9. URL http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.
- Lewis, J. A. (2004). In defence of the dichotomy. Phamaceutical Statistics 3:77–79.
- Rubin, D. B. (1976). Inference and missing data. Biometrika 63:581–592.
- Senn, S. (2003). Disappointing dichotomies. Phamaceutical Statistics 2:239–240.
- Snapinn, S. M., Jiang, Q. (2007). Responder analyses and the assessment of a clinically relevant treatment effect. Trials 8: article 31 (doi: 10.1186/1745-6215-8-31).
- Tsiatis, A. A. (2006). Semiparametric Theory and Missing Data. New York, NY: Springer.
- Uryniak, T., Chan, I. S. F., Fedorov, V. V., Jiang, Q., Oppenheimer, L., Snapinn, S. M., Teng, C.-H., Zhang, J. (2011). Responder analyses – a PhRMA position paper. Statistics in Biopharmaceutical Research 3:476–487.
- van der Vaart, A. W. (1998). Asymptotic Statistics. Cambridge, UK: Cambridge University Press.
- Whitem, H. (1982). Maximum likelihood estimation of misspecified models. Econometrica 50:1–25.